Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729271 · ClinicalTrials.gov registry record · Phase 4
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 148
- Enrollment target
NCT03729271 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 148 participants.
The verdict
NCT03729271, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.
Interventions
- DRUG Rifaximin
- DEVICE Glucose and lactulose hydrogen breath testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03729271
The ClinicalTrials.gov registry entry for NCT03729271 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifaximin is the first listed.
NCT03729271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03729271 about?
NCT03729271 is a clinical study titled "Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea". The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic sampl...
What is the current status of trial NCT03729271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 148 participants. The study started on 2020-01-09. Estimated completion is 2026-01-01.
What interventions are being tested in trial NCT03729271?
The interventions under investigation include: Rifaximin (DRUG), Glucose and lactulose hydrogen breath testing (DEVICE).
Who is sponsoring clinical trial NCT03729271?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.